{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreieimjmf2i2cb37q5omnolir73r2p6v3egrqvivfrrm7puxunltfjq",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mj5pawjt2tf2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreieglp4npepeuqbqarhtfsdvjw7sf72fd5ye6nsyx6ldz5gwupx6yi"
    },
    "mimeType": "image/jpeg",
    "size": 161434
  },
  "path": "/2026/04/10/skin-cancer-replimune-fda-approval/?utm_campaign=rss",
  "publishedAt": "2026-04-10T15:23:00.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Biotech",
    "Breaking News",
    "Pharma",
    "biotechnology",
    "Cancer",
    "drug development",
    "FDA",
    "Pharmaceuticals",
    "STAT+"
  ],
  "textContent": "A cancer drug candidate that, rightly or wrongly, became a flashpoint at FDA, fails on a second try at approval.",
  "title": "STAT+: Replimune skin cancer drug that became FDA flashpoint is rejected again",
  "updatedAt": "2026-04-10T15:49:00.000Z"
}